13 hours CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva Zacks
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug’s exclusivity in the United States till Feb. 25, 2035.
XCatalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug’s exclusivity in the United States till Feb. 25, 2035.
X